Get the latest news, insights, and market updates on CCCC (C4 Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
C4 Therapeutics (CCCC): Evaluating Valuation After Analyst Upgrade and Pipeline Developments
If you’re following C4 Therapeutics (CCCC), you’ve likely noticed the recent buzz around its stock. The latest spark was a high-profile analyst upgrade that brought renewed attention to the company’s drug pipeline. This optimistic view came just as anticipation built for C4 Therapeutics’ upcoming phase 1 data presentation at the International Myeloma Society meeting, prompting both longtime holders and new watchers to reconsider their stance on the stock. The upgrade and fresh confidence in... Sep 18, 2025 - $CCCC
Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?
Biogen recently announced that the U.S. FDA has accepted its investigational new drug (IND) application for BIIB142, an IRAK4 degrader developed in partnership with C4 Therapeutics, for exploration in autoimmune diseases. This milestone highlights the growing validation of C4 Therapeutics' targeted protein degradation platform and entitles the company to a US$2 million payment once clinical dosing begins. We'll explore how the FDA acceptance of Biogen's IND application for BIIB142... Sep 16, 2025 - $CCCC
Spotlight On Aware And 2 Other Promising Penny Stocks
As the S&P 500 and Nasdaq reach all-time highs, investors are keenly observing market shifts, including the unexpected dip in Producer Prices Index data. In such a climate, penny stocks continue to capture attention as they offer unique opportunities for growth at lower price points. Though often associated with smaller or newer companies, these stocks can provide substantial value when backed by strong financials and solid fundamentals. This article highlights three promising penny stocks... Sep 10, 2025 - $CCCC
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
Development Candidate Targeting IRAK4 Now Progressing Toward Clinical DevelopmentWATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to Sep 4, 2025 - $CCCC
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
C4T to Host Webcast on September 20, 2025 at 3 pm ETWATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET Sep 3, 2025 - $CCCC
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors
CAMBRIDGE, Mass., August 12, 2025--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic payloads to solid tumors, today announced the appointment of Andrew Hirsch, MBA, to the Company’s Board of Directors. Aug 12, 2025 - $CCCC
Spotlight On 3 Intriguing Penny Stocks With Market Caps As Low As $100M
As major U.S. indices rebound with solid weekly gains, investors are turning their attention to various opportunities within the market. Penny stocks, despite their somewhat outdated name, continue to offer intriguing prospects for those interested in smaller or newer companies. These stocks can provide a mix of affordability and growth potential when paired with strong financials, making them worth considering for investors seeking under-the-radar opportunities. Aug 8, 2025 - $CCCC
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which Is Aug 7, 2025 - $CCCC
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple